Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq slides to near one-month low as AI rout deepens
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent oil slips as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $38.08 +3.23%
EPS Growth %: -212.4%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
NTRP, FMCB, LOOP, More
EPS Growth %: -212.4%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
NTRP, FMCB, LOOP, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.12 million versus the consensus estimate of $21.65 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FMC tumbles 35% after slashing Q3 outlook over weak demand and inventory issues
- Accenture sets multi-year growth targets at investor day
- Active options: AVGO INTC MU DELL ASTS SOFI NBIS MSFT CIFR
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
